Jazz Pharmaceuticals PLC (OQ:JAZZ)

Business Focus: Pharmaceuticals

Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEC
Company Contact
Address: Fifth Fl
Waterloo Exchange, Waterloo Road
DUBLIN 4
Tel: 1-650-4962717
Website: https://www.jazzpharma.com
IR: See website
<
Key People
Bruce C. Cozadd
Chairman of the Board, Chief Executive Officer
Renee D. Gala
President, Chief Operating Officer
Philip Johnson
Chief Financial Officer, Executive Vice President
Robert Iannone
Executive Vice President, Global Head of Research and Development
Neena M. Patil
Executive Vice President, Chief Legal Officer
Patricia Carr
Senior Vice President, Chief Accounting Officer
Finbar Larkin
Senior Vice President - Technical Operations
Samantha Pearce
Senior Vice President, Europe and International
 
Business Overview
Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company's lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).
Financial Overview
For the fiscal year ended 31 December 2023, Jazz Pharmaceuticals PLC revenues increased 5% to $3.83B. Net income totaled $414.8M vs. loss of $224.1M. Revenues reflect Xyrem segment increase of 37% to $2.71B, Rylaze segment increase of 40% to $394.2M, United States segment increase of 4% to $3.49B, Europe segment increase of 12% to $269.2M. Net Income reflects Acquired in-process research and develop decrease of 96% to $19M (expense).
Employees: 2,800 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $10,930M as of Dec 31, 2023
Annual revenue (TTM): $3,834M as of Dec 31, 2023
EBITDA (TTM): $1,217M as of Dec 31, 2023
Net annual income (TTM): $414.83M as of Dec 31, 2023
Free cash flow (TTM): $1,049M as of Dec 31, 2023
Net Debt Last Fiscal Year: $4,092M as of Dec 31, 2023
Shares outstanding: 62,345,283 as of Feb 21, 2024
Index Membership: S&P 400 Mid Cap
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.